Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4075 |
Sulfatinib
KDR-IN-1,索凡替尼 |
VEGFR; FGFR; HER | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Sulfatinib (KDR-IN-1) (HMPL-012) 是一种有效且高度选择性的酪氨酸激酶抑制剂,可抑制VEGFR1/2/3,FGFR1和CSF1R,IC50范围为1 到 24 nM 之间。 | |||
T5466 |
Tyrosine kinase-IN-1
|
VEGFR; FGFR; FLT; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Tyrosine kinase-IN-1是一种多靶点酪氨酸激酶抑制剂,能够抑制KDR (IC50:4 nM),Flt-1 (IC50:20 nM),FGFR1 (IC50:4 nM) 和 PDGFRα (IC50:2 nM)。 | |||
T2500 |
Cediranib
AZD2171,NSC-732208,西地尼布 |
VEGFR; FLT; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Cediranib (AZD2171) 是一种可口服的高选择性VEGFR2抑制剂,对Flt1、KDR、Flt4、PDGFRα、PDGFRβ和c-Kit 的IC50值分别为小于1、小于3、5、5、36和 2nM。 | |||
T2624 |
OSI-930
OSI 930,噻尔非尼 |
Apoptosis; c-Fms; Raf; VEGFR; FLT; CSF-1R; Src; c-Kit | Angiogenesis; Apoptosis; MAPK; Tyrosine Kinase/Adaptors |
OSI-930 是 Kit,KDR 和 CSF-1R (c-Fms)的口服选择性抑制剂,IC50分别为 80 nM,9 nM 和 15 nM。它具有抗肿瘤活性,靶向肿瘤中的癌细胞增殖和血管生成。它还适度抑制 Flt-1,c-Raf 和 Lck,并且对 PDGFRα/β,Flt-3和 Abl 具有较弱的抑制活性。 | |||
T77108 | Olinvacimab | ||
Olinvacimab (TTAC-0001) 是一种人抗 VEGFR2单克隆抗体。Olinvacimab 抑制 VEGF 与 KDR 结合,Kd 值为 0.23 nM。Olinvacimab 具有抗血管生成活性。Olinvacimab 可用于复发性胶质母细胞瘤和乳腺癌的研究。 | |||
T68286 |
CE-245677 mesylate
|
||
CE-245677 is a selective, orally active Tie2 kinase inhibitor identified by Pfizer previously in development for the treatment of certain cancers. CE-245,677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50 of 4.7 and 1 nM, resp., displays >100x selectivity against a number of other angiogenic receptor tyrosine kinases (e.g. KDR, PDGFR, FGFR) and gene family panels, and demonstrates good oral absorption in in vivo rat PK studies (F=80%). |